MRI evidence that glibenclamide reduces acute lesion expansion in a rat model of spinal cord injury

Spinal Cord

Volumn 51, Issue 11, 2013, Pages 823-827

  Simard, J M ^a   Popovich, P G ^b   Tsymbalyuk, O ^a   Caridi, J ^a   Gullapalli, R P ^a   Kilbourne, M J ^c   Gerzanich, V ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

glibenclamide; MRI; progressive hemorrhagic necrosis; riluzole; spinal cord injury; Sur1 Trpm4 channel

Indexed keywords

#G 2539; GLIBENCLAMIDE; SULFONYLUREA RECEPTOR 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CONTUSION; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HINDLIMB; LOADING DRUG DOSE; LOCOMOTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPINAL CORD HEMORRHAGE; SPINAL CORD INJURY; TISSUE SECTION; UNITED STATES;

AGING; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GLYBURIDE; HEMORRHAGE; MAGNETIC RESONANCE IMAGING; RATS; RATS, LONG-EVANS; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 84887407727     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2013.99     Document Type: Article

References (28)

1. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal Cord 2006; 44: 523-529.
2. Steward O, Schauwecker PE, Guth L, Zhang Z, Fujiki M, Inman D et al. Genetic approaches to neurotrauma research: opportunities and potential pitfalls of murine models. Exp Neurol 1999; 157: 19-42.
3. Guth L, Zhang Z, Steward O. The unique histopathological responses of the injured spinal cord. Implications for neuroprotective therapy. Ann N Y Acad Sci 1999; 890: 366-384.
4. Simard JM, Tsymbalyuk O, Ivanov A, Ivanova S, Bhatta S, Geng Z et al. Endothelial sulfonylurea receptor 1-regulated NC(Ca-ATP) channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest 2007; 117: 2105-2113.
5. Kawata K, Morimoto T, Ohashi T, Tsujimoto S, Hoshida T, Tsunoda S et al. Experimental study of acute spinal cord injury: a histopathological study. No Shinkei Geka 1993; 21: 45-51.
6. Woo SK, Kwon MS, Ivanov A, Gerzanich V, Simard JM. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. J Biol Chem 2013; 288: 3655-3667.
7. Gerzanich V, Woo SK, Vennekens R, Tsymbalyuk O, Ivanova S, Ivanov A et al. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. Nat Med 2009; 15: 185-191.
8. Simard JM, Woo SK, Norenberg MD, Tosun C, Chen Z, Ivanova S et al. Brief suppression of Abcc8 prevents autodestruction of spinal cord after trauma. Sci Transl Med 2010; 2: 28ra29.
9. Simard JM, Tsymbalyuk O, Keledjian K, Ivanov A, Ivanova S, Gerzanich V. Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. Exp Neurol 2012; 233: 566-574.
10. Simard JM, Popovich PG, Tsymbalyuk O, Gerzanich V. Spinal cord injury with unilateral versus bilateral primary hemorrhage-effects of glibenclamide. Exp Neurol 2012; 233: 829-835.
11. Soblosky JS, Song JH, Dinh DH. Graded unilateral cervical spinal cord injury in the rat: evaluation of forelimb recovery and histological effects. Behav Brain Res 2001; 119: 1-13.
12. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006; 12: 433-440.
13. Simard JM, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009; 40: 604-609.
14. Simard JM, Woo SK, Tsymbalyuk N, Voloshyn O, Yurovsky V, Ivanova S et al. Glibenclamide-10-h treatment window in a clinically relevant model of stroke. Transl Stroke Res 2012; 3: 286-295.
15. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995; 12: 1-21.
16. Bilgen M, Abbe R, Liu SJ, Narayana PA. Spatial and temporal evolution of hemorrhage in the hyperacute phase of experimental spinal cord injury: in vivo magnetic resonance imaging. Magn Reson Med 2000; 43: 594-600.
17. Hackney DB, Ford JC, Markowitz RS, Hand CM, Joseph PM, Black P. Experimental spinal cord injury: MR correlation to intensity of injury. J Comput Assist Tomogr 1994; 18: 357-362.
18. Ohta K, Fujimura Y, Nakamura M, Watanabe M, Yato Y. Experimental study on MRI evaluation of the course of cervical spinal cord injury. Spinal Cord 1999; 37: 580-584.
19. Weirich SD, Cotler HB, Narayana PA, Hazle JD, Jackson EF, Coupe KJ et al. Histopathologic correlation of magnetic resonance imaging signal patterns in a spinal cord injury model. Spine 1990; 15: 630-638.
20. Balentine JD. Pathology of experimental spinal cord trauma. I. The necrotic lesion as a function of vascular injury. Lab Invest 1978; 39: 236-253.
21. Aarabi B, Simard JM, Kufera JA, Alexander M, Zacherl KM, Mirvis SE et al. Intramedullary lesion expansion on magnetic resonance imaging in patients with motor complete cervical spinal cord injury. J Neurosurg Spine 2012; 17: 243-250.
22. Popovich PG, Lemeshow S, Gensel JC, Tovar CA. Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury. Exp Neurol 2012; 233: 615-622.
23. Mishra MK, Ray D, Barik BB. Microcapsules and transdermal patch: a comparative approach for improved delivery of antidiabetic drug. AAPS Pharm Sci Tech 2009; 10: 928-934.
24. Tosun C, Koltz MT, Kurland DB, Ijaz H, Gurakar M, Schwartzbauer G et al. The Protective Effect of Glibenclamide in a Model of Hemorrhagic Encephalopathy of Prematurity. Brain Sci 2013; 3: 215-238.
25. Tator CH, Hashimoto R, Raich A, Norvell D, Fehlings MG, Harrop JS et al. Translational potential of preclinical trials of neuroprotection through pharmacotherapy for spinal cord injury. J Neurosurg Spine 2012; 17 (Suppl I), 157-229.
26. Wahl F, Stutzmann JM. Neuroprotective effects of riluzole in neurotrauma models: a review. Acta Neurochir Suppl 1999; 73: 103-110.
27. Wu Y, Satkunendrarajah K, Teng Y, Chow DS, Buttigieg J, Fehlings MG. Delayed postinjury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J Neurotrauma 2013; 30: 441-452.
28. Grossman RG, Fehlings M, Frankowski R, Burau KD, Chow D, Tator C et al. A prospective multicenter phase 1 matched comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma (e-pub ahead of print 16 July 2013).